1. Gelbard, A, Francis, DO, Sandulache, VC, Simmons, JC, Donovan, DT, Ongkasuwan, J. Causes and consequences of adult laryngotracheal stenosis. Laryngoscope. 2015;125(5):1137-1143. doi:10.1002/lary.24956
Google Scholar | Crossref | Medline2. Hseu, AF, Benninger, MS, Haffey, TM, Lorenz, R. Subglottic stenosis: a ten-year review of treatment outcomes. Laryngoscope. 2014;124(3):736-741. doi:10.1002/lary.24410
Google Scholar | Crossref | Medline | ISI3. Hillel, AT, Ding, D, Samad, I, Murphy, MK, Motz, K. T-Helper 2 lymphocyte immunophenotype is associated with iatrogenic laryngotracheal stenosis. Laryngoscope. 2019;129(1):177-186. doi:10.1002/lary.27321
Google Scholar | Crossref | Medline4. Gelbard, A, Katsantonis, NG, Mizuta, M, et al. Idiopathic subglottic stenosis is associated with activation of the inflammatory IL-17A/IL-23 axis. Laryngoscope. 2016;126(11):E356-E361. doi:10.1002/lary.26098
Google Scholar | Crossref5. Verma, R, Foster, RE, Horgan, K, et al. Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer. Breast Cancer Res. 2016;18(1):10. doi:10.1186/s13058-015-0669-x
Google Scholar | Crossref | Medline6. Azab, B, Alassaf, A, Abu-Humdan, A, et al. Genotoxicity of cisplatin and carboplatin in cultured human lymphocytes: a comparative study. Interdiscip Toxicol. 2019;12(2):93-97. doi:10.2478/intox-2019-0011
Google Scholar | Crossref | Medline7. Rébé, C, Ghiringhelli, F. Cytotoxic effects of chemotherapy on cancer and immune cells: how can it be modulated to generate novel therapeutic strategies? Future Oncol. 2015;11(19):2645-2654. doi:10.2217/fon.15.198
Google Scholar | Crossref | Medline8. Adjei, AA. Pharmacology and mechanism of action of pemetrexed. Clin Lung Cancer. 2004;5:S51-S55. doi:10.3816/CLC.2004.s.003
Google Scholar | Crossref | Medline9. Istifli, ES, Topaktaş, M. Genotoxicity of pemetrexed in human peripheral blood lymphocytes. Cytotechnology. 2013;65(4):621-628. doi:10.1007/s10616-012-9516-4
Google Scholar | Crossref | Medline10. McCoy, MJ, Lake, RA, van der Most, RG, Dick, IM, Nowak, AK. Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies. Br J Cancer. 2012;107(7):1107-1115. doi:10.1038/bjc.2012.362
Google Scholar | Crossref | Medline11. Thorn, CF, Oshiro, C, Marsh, S, et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics. 2011;21:440-446. doi:10.1097/FPC.0b013e32833ffb56
Google Scholar | Crossref | Medline | ISI12. Levick, SP, Soto-Pantoja, DR, Bi, J, et al. Doxorubicin-induced myocardial fibrosis involves the neurokinin-1 receptor and direct effects on cardiac fibroblasts. Heart Lung Circ. 2019;28(10):1598-1605. doi:10.1016/j.hlc.2018.08.003
Google Scholar | Crossref | Medline13. Nevadunsky, NS, Mbagwu, C, Mizrahi, N, Burton, E, Goldberg, GL. Pulmonary fibrosis after pegylated liposomal doxorubicin in a patient with uterine papillary serous carcinoma. J Clin Oncol. 2013;31(10):e167-e169. doi:10.1200/JCO.2012.44.5767
Google Scholar | Crossref | Medline14. Kirkbride, P, Hatton, M, Lorigan, P, Joyce, P, Fisher, P. Fatal pulmonary fibrosis associated with induction chemotherapy with carboplatin and vinorelbine followed by CHART radiotherapy for locally advanced non-small cell lung cancer. Clin Oncol. 2002;14(5):361-366. doi:10.1053/CLON.2002.0119
Google Scholar | Crossref15. Sotiriou, C, van Houtte, P, Klastersky, J. Lung fibrosis induced by paclitaxel. Support Care Cancer. 1998;6(1):68-71. doi:10.1007/S005200050135
Google Scholar | Crossref | Medline16. Tomii, K, Kato, T, Takahashi, M, et al. Pemetrexed-related interstitial lung disease reported from post marketing surveillance (malignant pleural mesothelioma/non-small cell lung cancer). Jpn J Clin Oncol. 2017;47(4):350-356. doi:10.1093/jjco/hyx010
Google Scholar | Crossref | Medline17. Prince, GT, Cameron, MC, Fathi, R, Alkousakis, T. Intralesional and laser-assisted 5-fluorouracil in dermatologic disease: a systematic review. J Drugs Dermatol. 2018;17(3):274-280.
Google Scholar | Medline